Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Qualigen Therapeutics ( (QLGN) ) is now available.
On August 21, 2025, Qualigen Therapeutics, Inc. amended its secured promissory note with Marizyme, Inc., increasing the principal balance to $4,451,462.18. This agreement includes a security interest in Marizyme’s assets and a conditional forbearance from demanding payment for one year, impacting the company’s financial arrangements and stakeholder interests.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Average Trading Volume: 837,671
Technical Sentiment Signal: Sell
Current Market Cap: $3.14M
For an in-depth examination of QLGN stock, go to TipRanks’ Overview page.